Nicaragua vs Singapore: HIV/AIDS deaths averted by antiretroviral therapy
Nicaragua
333 deaths
in 2022
Singapore
331.57 deaths
in 2023
Nicaragua rank
100th
Singapore rank
102nd
HIV/AIDS deaths averted by antiretroviral therapy over time
- Nicaragua
- Singapore
How they compare
Nicaragua currently reports 333 deaths against 331.57 deaths in Singapore, a difference of 1.43 deaths.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Singapore ahead.
Nicaragua ranks 100th and Singapore ranks 102nd of 157 countries.
Across the 4 decades both report, Nicaragua averaged higher in 3 and Singapore in 1.
Head to head by decade
| Decade | Nicaragua | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0.6975 deaths | 0.6975 deaths | Singapore |
| 2000s | 55.8 deaths | 53.47 deaths | 2.33 deaths | Nicaragua |
| 2010s | 288.7 deaths | 253.24 deaths | 35.46 deaths | Nicaragua |
| 2020s | 346 deaths | 337.55 deaths | 8.45 deaths | Nicaragua |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Nicaragua or Singapore?
- Nicaragua, at 333 deaths against 331.57 deaths in Singapore as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Nicaragua and Singapore?
- 1.43 deaths, with Nicaragua ahead.
- How many years of comparable data are there for Nicaragua and Singapore?
- 33 years are reported by both, from 1990 to 2022.
- How do Nicaragua and Singapore rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Nicaragua ranks 100th and Singapore ranks 102nd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.